Esperion to acquire Corstasis for cardiovascular franchise expansion
Esperion is set to acquire Corstasis Therapeutics in a strategic move to enhance its cardiovascular franchise through the addition of Enbumyst, a bumetanide nasal spray. This acquisition underscores Esperion’s commitment to expanding its portfolio in the cardiovascular space, particularly as the demand for innovative treatment options continues to rise. The integration of Enbumyst into Esperion’s…









